We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS)

This study is currently recruiting participants.
Verified September 2017 by Alliance Foundation Trials, LLC.
ClinicalTrials.gov Identifier:
First Posted: July 31, 2015
Last Update Posted: September 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Austrian Breast & Colorectal Cancer Study Group
NSABP Foundation Inc
Breast International Group
Information provided by (Responsible Party):
Alliance Foundation Trials, LLC.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2025
  Estimated Primary Completion Date: September 2020 (Final data collection date for primary outcome measure)